Close
Close

La Jolla Pharmaceutical Company - Vasodilatory Shock

Partner

Not provided

Rare Disease

Vasodilatory Shock

Sponsor

La Jolla Pharmaceutical Company

Access Program Information

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Contact

Contact: Tammy G Boyce (619-933-7176)

Locations

Free Newsletter